spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  antiemetic 

 HSMN NewsFeed - 1 Jul 2021
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF(TM) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 22 Oct 2019
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI(R) Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Apr 2018
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2018
Acacia Pharma Announces FDA Acceptance of NDA Filing For BAREMSIS(R) for the Management of Post-operative Nausea & Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Aug 2016
Acacia Pharma Announces Positive Results From a Pivotal Phase 3 Trial of BAREMSIS(TM) for the Treatment of Post-Operative Nausea & Vomiting
Biopharmaceuticals
 HSMN NewsFeed - 10 Aug 2016
Heron Therapeutics Announces U.S. FDA Approval of SUSTOL(R) (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jul 2016
Insys Therapeutics Announces FDA Approval of Syndros(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 May 2015
The European Commission Approves ALOXI(R) (palonosetron HCl) Injection to Prevent Nausea and Vomiting Due to Chemotherapy in Children as Young as One Month
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Oct 2014
FDA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jan 2014
Insys Announces Details of Product Development Pipeline
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 12 Nov 2013
A.P. Pharma Announces Pipeline Expansion
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 17 May 2013
New Study Shows Effect of Neupro(R) (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2013
FDA Approves Second Drug in BD Simplist(TM) Prefilled Injectable Line of Products
Biopharmaceuticals Devices Drug Delivery Generics FDA
 HSMN NewsFeed - 18 Jan 2013
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jul 2012
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 3 Apr 2012
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2010
Study Showed the Clinically Significant Therapeutic Benefit of Neupro(R) (rotigotine transdermal system) in the Treatment of Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2010
Neupro(R) (rotigotine) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 17 Jun 2010
Neupro(R) (rotigotine transdermal system) Showed Significant Benefit on Early Morning Motor Control, Sleep and Nocturnal Symptoms in Patients With Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Apr 2010
UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro(R) (Rotigotine)
Biopharmaceuticals Drug Delivery Neurology FDA
 HSMN NewsFeed - 14 Apr 2010
Sagent Pharmaceuticals Announces FDA Approval of Granisetron Hydrochloride Injection, USP
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 13 Apr 2010
New Data Show Sustained 5-Year Benefit of Neupro(R) (Rotigotine Transdermal System) for Symptoms of Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 8 Sep 2009
Salix Receives FDA Marketing Approval for METOZOLV ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 5 Jun 2009
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2008
FDA Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 4 Aug 2008
Meda Acquires European Businesses from American Valeant and Enters the Russian Market
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 9 Jul 2008
Par Pharmaceutical to Launch meclizine HCL Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 30 May 2008
NCCN Previews Chemotherapy Order Templates(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
NovaDel Announces European License Agreement for Ondansetron Oral Spray
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 Apr 2008
Akorn-Strides, LLC Announces FDA Approvals for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 13 Mar 2008
Hawthorn Pharmaceuticals, Inc. Receives FDA Approval on Granisol(TM) Oral Solution
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Mar 2008
FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2008
FDA Approves EMEND(R) (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jan 2008
Teva Announces Approval of Generic Kytril(R) Injection and Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 7 Nov 2007
Axiom Worldwide's International Medical Advisory Board Steering Committee Issues Consensus Statement Regarding the Axiom Protocols!
Devices Neurosurgery Orthopaedic
 HSMN NewsFeed - 4 Oct 2007
Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Aug 2007
Hana Biosciences Licenses North American Commercial Rights for Zensana(TM) to Par Pharmaceutical in a $50 Million Deal
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Jul 2007
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2007
Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet(R) in Cancer Chemotherapy-Induced Neuropathic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Feb 2007
Hana Biosciences Reports Likely Delay in Launch of Zensana(TM)
Biopharmaceuticals
 HSMN NewsFeed - 26 Dec 2006
Hospira Launches Ondansetron Injection
Biopharmaceuticals Generics
 HSMN NewsFeed - 2 Nov 2006
Par Announces Termination of Cesamet(TM) Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Aug 2006
FDA Accepts for Review NDA Filing for Zensana(TM) (Ondansetron HCI) Oral Spray
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jul 2006
FDA Approves EMEND(R) (aprepitant), Merck's Antiemetic Therapy, for the Prevention of Postoperative Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2006
FDA Approves EMEND(R) (aprepitant), in Combination with Other Antiemetics, for the Prevention of Nausea and Vomiting in Cancer Patients Undergoing Moderately Emetogenic Chemotherapy
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 27

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 27 additional stories matching:
antiemetic
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.